A15.0 — Pulmonary Tuberculosis
Approved39M · medication — Standard 6-month RIPE regimen
Insurer Rationale
The requested first-line antituberculous regimen is approved for confirmed drug-sensitive pulmonary tuberculosis.
Reasoning Chain
This approval follows the guideline pathway. The diagnosis is confirmed, the isolate is drug-sensitive, and early standard therapy is the correct public-health and patient-level intervention.
Reasoning Chain
Findings
Persistent cough, Night sweats, Weight loss, Positive sputum AFB, Household contacts
Diagnosis
Pulmonary tuberculosis (microbiologically confirmed)
Assessment
Drug-sensitive TB treatment review — Standard RIPE therapy is indicated immediately once drug-sensitive TB is confirmed.
Guideline action
Begin standard six-month RIPE regimen with public-health follow-up
Verdict
Approval is clinically correct because prompt standard therapy is the evidence-based first-line treatment for drug-sensitive pulmonary TB.
Clinical Evidence
NICE Guideline NG33 — Tuberculosis
Active TB treatment
Drug-sensitive pulmonary TB should receive standard multidrug treatment without delay.
WHO Consolidated Guidelines on Tuberculosis (2024)
Drug-sensitive TB
A standard intensive-plus-continuation regimen remains first-line for confirmed drug-sensitive disease.